Cellebrite DI Ltd.

As of November 14, 2025, Cellebrite DI Ltd. has an attractive valuation grade, indicating it may be undervalued with a Price to Book Value of 10.89 and an EV to EBITDA ratio of 50.27, despite its loss-making status, especially when compared to peers like Clearwater Analytics and SolarWinds.

As of November 14, 2025, Cellebrite DI Ltd. is considered an attractive investment due to its undervaluation despite challenges like a negative ROE and loss-making status, especially when compared to peers like Clearwater Analytics and Zeta Global.

As of November 14, 2025, Cellebrite DI Ltd. is considered undervalued with a valuation grade of attractive, despite a negative ROE and mixed short-term performance, having outperformed the S&P 500 over three years but declined year-to-date.

As of October 3, 2025, Cellebrite DI Ltd. shows a neutral technical trend with mixed signals, being mildly bullish on weekly indicators but mildly bearish on monthly ones, while underperforming the S&P 500 year-to-date but significantly outperforming it over the last three years.

As of October 3, 2025, Cellebrite DI Ltd. has a neutral technical trend with mixed indicators, showing a mild bullish stance on weekly charts but mildly bearish on monthly charts, while underperforming the S&P 500 year-to-date but achieving a strong 3-year return of 366.67%.

As of October 3, 2025, Cellebrite DI Ltd. shows a neutral technical trend with mixed signals, underperforming the S&P 500 year-to-date but outperforming it over the last month, suggesting a cautious investment approach.

As of September 9, 2025, Cellebrite DI Ltd. shows a mildly bullish trend with mixed signals from technical indicators, having outperformed the S&P 500 recently but down 18.88% year-to-date, despite a strong 3-year return of 308.92%.

As of August 8, 2023, Cellebrite DI Ltd. is considered overvalued and risky due to its negative return on equity of -53.38%, a high price-to-book ratio of 10.89, and an EV to EBITDA ratio of 50.27, especially in comparison to more attractive peers like Clearwater Analytics and Clear Secure, despite a strong three-year return of 308.92%.

As of August 8, 2023, Cellebrite DI Ltd. is considered overvalued with a risky valuation grade due to negative financial metrics, including a price-to-book ratio of 10.89, an EV to EBITDA ratio of 50.27, and a troubling -53.38% return on equity, while its year-to-date return of -26.83% significantly underperforms the S&P 500's 2.44%.

As of June 2, 2025, Cellebrite DI Ltd. is in a bearish trend, supported by bearish signals from the weekly MACD and KST, daily moving averages, and Dow Theory, despite mildly bullish conditions indicated by the monthly Bollinger Bands.

Cellebrite DI Ltd. is a small-cap software company with recent net sales of $108 million and a net profit of $17 million. It has a market cap of $3.83 billion, but is currently loss-making with a P/E ratio of NA and no dividend yield.

As of Jun 18, Cellebrite DI Ltd. has a market capitalization of 3,827.40 million, with net sales of 419.17 million and a net profit of -194.23 million over the latest four quarters. The company reported shareholder's funds of 336.02 million and total assets of 696.57 million as of Dec 24.